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Dorothee Leunen1, Isabelle Jambaqué1,2,3,4, Olivier Dulac1,2,3,4, Georges Dellatolas5 and Catherine Chiron1,2,3,4Abstract
Background: Dravet syndrome (DS) is currently considered as an epileptic encephalopathy, a condition in which
epilepsy causes deterioration or developmental delay but preliminary data suggested that cognitive course may
worsen independently from epilepsy. Our objective was to prospectively analyze the neuropsychological features in
a large cohort of DS patients and its relationships with epilepsy and SCN1A mutation.
Methods: 81 examinations were performed in 67 patients with typical DS (9m-24y, 15 longitudinally studied) using
Brunet-Lezine (developmental/intelligence quotient [DQ/IQ] and DQ sub-scores), Achenbach, Conners, and a
semi-quantitative psychomotor score (SQPS). We studied the correlation between DQ/IQ/SQPS and age, epilepsy
characteristics, and whether patients presented SCN1A mutation.
Results: DQ/IQ significantly decreased with age (r = −.53, p < .001), from normal before 2y (mean 80, range 64–105)
to low after 3y (mean 48, range 30–69), with hyperactivity and attention disorders hampering learning abilities
especially up to 6y. However, raw (not age-adjusted) DQ sub-scores increased with age during the first decade,
showing that there is no regression. We did not find any significant correlation between DQ/IQ at last evaluation
and epilepsy data, i.e. first seizure (age, type, duration, fever), seizures during the course (type, fever sensitivity),
status epilepticus (age of onset, number, fever), photosensitivity, and treatment, except for myoclonus and focal
seizures which were associated with a lower QD/IQ after 3y. SCN1A mutated patients (n = 58) seemed to exhibit
worse psychomotor course than non-mutated ones (n = 9) (severe SQPS in 26% vs 0%), although their epilepsy
tended to be less severe (tonic seizures in 12% vs 44% [p = 0.04], first status epilepticus before 6 m in 26% vs 67%
[p = .02], mean number of SE 2.5 vs 4.5 [p = .09]). DQ sub-scores were dissociated throughout the whole course:
from onset hand-eye coordination was significantly lower than language, posture and sociability (p < .01).
Dissociation seemed to be more frequent in mutated than in non-mutated patients (motor SQPS was normal for in
77% vs 44% [p = 0.017] whereas language SQPS was normal for 47% vs 100%).
Conclusions: Although psychomotor/cognitive delay declines with age, there is no regression. In addition,
encephalopathy is not a pure consequence of epilepsy but SCN1A mutation seems to play an additional, direct role.
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Dravet syndrome (DS) is a severe epilepsy presenting in
the first year of life with clonic seizures triggered by
fever, often unilateral and long lasting in a child with
previously normal development. Other seizure types
may develop between one and four years of age, includ-
ing myoclonic jerks, focal seizures and atypical absences.
Electroencephalogram (EEG) is usually normal at onset,
and then shows slowing of basal activity with asymmet-
rical spikes or polyspikes-waves [1,2]. In addition to
pharmacoresistant seizures and frequent episodes of sta-
tus epilepticus (SE) often triggered by fever, severity of
the condition results from the frequent occurrence of
progressive worsening of psychomotor delay and sudden
death. Mutations in SCN1A have been identified in 75%
of DS patients [3], and mutations in PCDH19 were
found in 10% of the SCN1A-negative population [4].
Developmental delay in DS is usually considered as a
result of severe epilepsy, and the term “epileptic enceph-
alopathy” therefore often applied [5-7]. Occurrence of
SE and early spikes on EEG proved to be predictors of a
worse developmental outcome in a large DS cohort of
SCN1A mutated patients [8]. However preliminary data
question this relationship between cognitive outcome
and the course of epilepsy. Two patients with SCN1A
truncation and severe cognitive decline presented with
divergent epilepsy severity [9]. Cognitive scores were not
related to the frequency of convulsive seizures in a series
including 16% of SCN1A-negative patients [10]. DS
patients with PCDH19 mutations seem to develop better
than those with SCN1A mutations despite the occur-
rence of explosive convulsive clusters [4]. The first
attempt to detect any difference in cognitive outcome
according to the presence or not of SCN1A mutation
was unsuccessful [11].
Whether Nav.1 dysfunction plays a role in the cogni-
tive decline independently from the epilepsy has not
been proved so far. While epilepsy features in children
affected by DS have been described in detail for a long
time [1,12,13], neurodevelopmental features were only
recently addressed and available data mostly consist of
small and/or retrospective series [7-11,14,15], sometimes
without formal neuropsychological testing [8].
The aim of this study was to analyze the neuropsycho-
logical and behavioral features prospectively in a large
cohort of patients with DS and its relation with SCN1A
mutation and the characteristics of epilepsy.
Methods
All children and adolescents followed at the Neuropediatric
Department of Necker Hospital, with clinical and EEG fea-
tures of typical DS, based on the ILAE classification [16],
were prospectively enrolled in this study from January 2006.
Inclusion criteria were the following: i) normal infant withnormal EEG and without preexisting cerebral lesion, devel-
oping normally until the first seizure occurring before one
year of age, ii) refractory clonic or tonic-clonic seizures
affecting one or both sides simultaneously or alternatively,
with eventually additional seizure types during follow-up, iii)
exclusion of any other identified epilepsy syndrome. All
SCN1A negative patients were tested for PCDH19 and those
with PCDH19mutation were excluded.
Clinical data were assessed prospectively from 2006 to
2010 by the same three pediatric neurologists (RN, OD,
CC). Those obtained before 2006 were retrieved from
the medical files. Demographic data included familial
(history of febrile seizures/epilepsy) and personal (pre-
and peri-natal) antecedents. Epilepsy data (used as
variables) included first seizure (age, febrile/afebrile,
status epilepticus [SE]/non SE [the term SE designated
seizures lasting more that 30 minutes], unilateral/
generalized), seizures during course (presence or absence
of tonic-clonic, clonic, tonic, absences, myoclonic or
focal seizures and sensitivity to fever or not), SE (pres-
ence or absence of SE, and if any: age at first SE, number
of SE, sensitivity to fever or not), photosensitivity (yes/
no on EEG), and treatment (therapy used, age at stiri-
pentol introduction if any, use or not of any antiepileptic
drugs considered inappropriate for DS and duration if
any). Neurological data included gait and neurological
examination.
Mutation analysis of the SCN1A was performed by dir-
ect sequencing followed, in negative patients, by multi-
plex ligation probe amplification (MLPA) as reported
previously [4]. Patients were considered mutated when
they presented any abnormality on SCN1A gene (muta-
tion, rearrangement, deletion) and “non-mutated” when
they had no abnormality detectable on SCN1A.
Neuropsychological evaluations were prospectively
performed by the same neuropsychologist from 2006.
Raw data of evaluations performed before 2006 were
reanalyzed and used for this study. Neurodevelopmental
features and adaptation were assessed according to
age and level of collaboration using Wechsler Scales
(WPPSI, WISC-IV) (IQ, intellectual quotient) [17,18],
Brunet-Lezine Developmental Scale (DQ, developmental
quotient) with sub-scores to be completed up to 6 years
(the superior age at which the Brunet-Lezine scale is
applicable) [19]. Behavior troubles were screened by clin-
ical observation, parent’s interview, Achenbach Child
Behavior Checklist and Conners Rating Scale [20,21]. In
addition, psychomotor development was assessed by the
pediatric neurologist with the neuropsychologist during
free play using a semi-quantitative psychomotor scale
(SQPS) (no/moderate/severe delay) for global, motor and
language development.
For the present analysis, we used all the DQ/IQ and
DQ sub-scores obtained during the whole follow-up,
Table 1 Clinical, cognitive and genetic data
Clinical and cognitive
characteristics
SCN1A+ SCN1A- Total
N 58 9 67
Sex: boys N (%) 33 (56.9) 6 (66.7) 39 (58.2)
Age in years: mean (SD)
at last follow-up 9.1 (5.3) 8.7 (4.6) 9.0 (5.2)
at first examination 4.0 (5.4) 4.0 (2.7) 4.0 (5.2)
Follow-up duration 5.1 (4.2) 4.7 (5.6) 5.0 (4.4)
Family history for
seizures: N (%)
21 (36.2) 4 (44.4) 25 (37.3)
Dravet Syndrome 3 (5.2) 0 3 (4.5)
Febrile seizures 14 (24.1) 3 (33.3) 17 (25.4)
Febrile seizures plus 2 (3.4) 0 2 (3.0)
Epilepsy 8 (13.8) 1 (11.1) 9 (13.4)
Age at first seizure: N (%)
0-3 months 6 (10.3) 1 (11.1) 7 (10.4)
3-6 months 29 (50.0) 5 (55.6) 34 (50.7)
6-9 months 18 (31.0) 1 (11.1) 19 (28.4)
> 9 months 5 (8.3) 2 (22.2) 7 (10.5)
Type of seizures: N (%)
Tonic-clonic 51 (87.9) 8 (88.9) 59 (88.1)
Absences 32 (55.2) 5 (55.6) 37 (55.2)
Myoclonic 29 (50.0) 6 (66.7) 35 (52.2)
Tonic 7 (12.1) 4 (44.4) 11 (16.4)
Clonic 38 (65.5) 7 (77.8) 45 (67.2)
Partial 23 (39.7) 3 (33.3) 26 (38.8)
Sensitivity to fever 51 (87.9) 7 (77.8) 58 (86.6)
Photosensitivity 11 (19.0) 4 (44.4) 15 (22.4)
Status Epilepticus (SE)
Present: N (%) 46 (79.3) 6 (66.7) 52 (77.6)
Age at first SE: N (%)
0-3 months 0 1 (16.7) 1 (1.9)
3-6 months 12 (26.1) 3 (50.0) 15 (28.8)
6-9 months 14 (30.4) 0 14 (26.9)
9-12 months 7 (15.2) 1 (16.7) 8 (15.4)
>12 months 13 (28.3) 1 (16.7) 14 (26.9)
Neurological features: N (%)
Ataxia/Gait disorders* 45 (77.5) 4 (44) 49 (73)
Pyramidal signs 4 (6.9) 1 (11.1) 5 (7.5)
Last DQ/IQ
Mean (SD) 53.4
(20.9)
42.9
(11.3)
51.9
(20.2)
Range 30-105 30-65 30-105
Age at last DQ/IQ (years)
Mean (SD) 6.0 (4.6) 8.7 (3.7) 6.4 (4.5)
Range 1.1-23.9 4.6-16.1 1.1-23.9
Table 1 Clinical, cognitive and genetic data (Continued)
Semi-quantitative psychomotor
score
(SQPS)
Mild 33 (57.9) 5 (55.6) 38 (57.6)
Moderate 9 (15.8) 4 (44.4) 13 (19.7)
Severe 15 (26.3) 0 15 (22.7)
N = number, SD = standard deviation, DQ/IQ = developmental/intellectual
quotient. *p = 0.017.
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from the last evaluation.
We studied the relationship between psychomotor/
cognitive/behavioral profile, age, epilepsy, and genetic
background. First we studied the relationship between
DQ/IQ scores, DQ sub-scores, Achenbach, and Conners,
on one hand, and age on the other hand. A special ana-
lysis of the changes with age in DQ/IQ and DQ sub-
scores was performed in the sub-population of patients
longitudinally assessed. Secondly we studied the rela-
tionships between DQ/IQ and epilepsy variables. Thirdly
we studied the relationships between the presence or
absence of SCN1A abnormality on one hand, and neuro-
developmental scores at last evaluation (DQ/IQ, DQ
sub-scores, and semi-quantitative psychomotor assess-
ment) and epilepsy variables on the other hand. Statis-
tical analyses were performed using bivariate and
univariate tests: correlation for continuous variables,
chi-square and if necessary Fisher exact for categorical
variables, and t-test and if necessary signed rank test to
compare means.
Patients
The clinical, cognitive and genetic data are summarized
in (Table 1).
Demographics
The cohort consisted of 67 patients (39 males and 28
females) with a median age of nine years at the time of
last follow-up (range: 1.8 – 24 years). The mean follow-
up was five years.
A positive family history for seizures was reported in
25 patients: DS in three (two sibs and the brother of an
affected sister not included), febrile seizures in 19, other
epilepsies in nine. Seizures phenotype, cognitive and
behavioural profile were not similar in both DS sibs.
Personal antecedents included intrauterine growth delay
in three patients (4%), neonatal respiratory distress in
three (4%), and prematurity in two (3%).
Clinical data
All patients presented the first seizure between one and
12 months of age, mostly between three and six months.
020
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Figure 1 Developmental/intelligence quotient in the whole
population.
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(37%). It was long-lasting, evolving to SE in 23 (34%).
During follow-up, seizures were polymorphous in all
patients, mainly nocturnal in 12 of them, and 15 patients
presented with clinical photosensitivity. Seizures were
mostly tonic-clonic or clonic, atypical absences and
myoclonic seizures were present in about half the cases,
and 16% of patients experienced tonic seizures. SE was
reported in 78% of patients, occurring up to the age of
8 years, 79% of SE occurred during the first year of life.
SE and shorter seizures were triggered by fever in
respectively 70% and 87% of the children.
At last examination, gait disturbance affected 49
patients (73%) and pyramidal signs five (7%). Two
children died, respectively at the ages of 3.5 and 6.5 years:
the first in a context of SUDEP during sleep with no
witnessed seizure, and the second in the course of a
brainstem tumor that was refractory to chemotherapy
and offered no surgical possibility.
Treatment
Fifty six patients (84%) received the valproate, stiripentol
and clobazam (VPA-STP-CLB) tri-therapy. Thirty pa-
tients received additional antiepileptic drugs, mainly
topiramate or levetiracetam (45%), and the ketogenic
diet (23%). A few patients received zonisamide (8%) or
clonazepam (6%). Seven patients (10%) did not receive
stiripentol but the combination of valproate, clobazam
and topiramate.
Stiripentol was introduced at a median age of
28 months (range: 0.5-12 years), in adjunction to valpro-
ate and clobazam in 43 patients, or in adjunction to
valproate and concomitantly to clobazam in 11 patients.
In 2 patients, the 3 drugs were introduced together, after
the first SE.
Seventeen patients (25%) received during the first
three years of life drugs that could be considered
inappropriate for this condition: carbamazepine in 11
patients, lamotrigine in 8 and vigabatrin in 4. All
patients treated with these drugs experienced worsening
of seizure frequency and for all it was withdrawn within
less than three months.
Genetics
Mutations and rearrangements in SCN1A were found in
58 patients (86%). Mutations were de novo in 92% of
cases, including missense mutations in 18 (26%), and
frameshift or non-sense mutations in 40 (60%). MLPA
identified no deletions in patients with no mutations.
Consent
Neuropsychological evaluation was part of the usual
clinical work-up of Dravet patients in our practice.Informed consent was obtained from the patient’s
parents for the publication of this report.
Results
We performed a total of 81 neuropsychological evalua-
tions with Wechsler or Brunet-Lezine Scales in this
series (67 patients). In 10 patients (15%) such evaluation
was not possible because of opposing (7 cases) or autis-
tic (3 cases) behavior, and we could score 85% of our
series. We also obtained responses for Conners scale in
58 patients and for Achenbach in 59.
Cognitive development according to age
Overall series
Among all evaluations, a significant decrease of DQ or
IQ with increasing age was observed (r = −.53, p < .001;
Spearman’s Rho = −.66, p < .001) (Figure 1). Up to the
age of three years mean DQ/IQ remained generally
above 70 (before two years of age mean = 79.5, SD =
12.0, range 64–105 and before three years mean = 73.7,
SD = 15.0, range 36–105). There was a strong decrease
after the age of three (mean = 48.0, SD = 18.9, range
30–69). Only four patients remained with an IQ above
60 after the age of five; all four had SCN1A mutation
that was inherited for only the fourth patient.
One had an IQ of 93 at 5.4 years and at 73 at 6.9 years.
He presented three episodes of SE during the first two
years and received the tri-therapy (VPA-STP-CLB) since
the age 18 months. He was almost free of seizures till
the age of five and presented frequent nocturnal tonic-
clonic seizures since this age. He attended normal school
program with a personalized assistant teacher. The
second patient had an IQ of 74 at 5.8 and 65 at nine
years. He required personalized support in school and
was to be addressed to a special educational program.
He had frequent episodes of SE and frequent poly-
morphous seizures on VPA-STP-CLB. The third patient
had an IQ of 96 at the last evaluation at 5.6 years, and
was still in the main school stream. He had rare episodes
of SE and became almost seizure free on topiramate (he
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at nine years of age, and attended normal school. He
had frequent febrile seizures, two episodes of SE and fre-
quent atypical absences with generalized tonic-clonic
seizures. Seizures were controlled with valproate and
clobazam. He presented behavior troubles.
All patients other than these four were following a
special educational program out of the normal school.
The Brunet-Lezine (children less than 6 years) sub-
scores disclosed heterogeneity between the four tested
fields: hand-eye coordination (oculo-motor), language,
posture and sociability. Hand-eye coordination DQ sub-
score (mean = 62.0, SD = 16.8) was significantly lower
(p < .01, signed rank test) than respectively language
(mean = 72.3, SD = 17.6), socialization (73.4, SD = 15.8)
and posture (mean = 76.5, SD = 16.9) DQ sub-scores.
Difference between language, posture and sociability
skills was not significant. All patients had acquired lan-
guage at last evaluation and those over six years were
able to build sentences. All could walk with a certain
extent of gait disturbance except for one who required a
wheel chair.
The Achenbach scale showed abnormal sub-scores
identifying social problems and attention deficit.
Although the mean scores remained under 70, they were
in the gray area for both fields (T-score between 60 andFigure 2 Course of the developmental/intelligence quotient and sub-70). The Conners scale showed abnormal learning abil-
ities (>70) and a hyperactivity score in the gray area
(Figure 2). These findings were concordant with the
clinical evaluation of these patients that pointed to
hyperactivity and attention deficit, namely between two
and five years of age, when the Conners test exhibited
the highest pathological hyperactivity score (>70).
Twenty percent of the patients mainly within this age
range required methylphenidate, with clinical and scores’
improvement. Although some autistic features were
reported by parents and educators and on clinical obser-
vation, mainly consisting of repetitive body movements,
ritualistic behavior and poor eye contact, these symp-
toms were often isolated and patients did not fulfill the
clinical criteria for autism except in 3 cases.
Longitudinal series
Fifteen patients had two neuropsychological evaluations.
The first evaluation was performed at a mean age of
34 months (SD = 22, range 9–91), and the second at a
mean age of 66 months (SD = 43, range 15–175). DQ/IQ
at first evaluation was significantly higher than at second
evaluation (mean of the difference = 15.1, SD = 19.8,
p < .01 signed rank test). Twelve out of 15 patients
exhibited a decline DQ/IQ pattern similar to the overall
series (Figure 2a). Only two of the 15 remained withscores.
Nabbout et al. Orphanet Journal of Rare Diseases 2013, 8:176 Page 6 of 8
http://www.ojrd.com/content/8/1/176DQ/IQ over 60 after 5 years of age. Although IQ/DQ
score continued dropping in all 15 patients, they contin-
ued acquiring new abilities as disclosed by persistent
although slow increase in the absolute values of DQ
sub-scores (Figure 2b,c,d). This slow progress was also
clinically obvious.
Cognitive development according to epilepsy
For overall evaluations, statistical analysis failed to detect
any significant correlation between global DQ/IQ and
epilepsy variables, i.e. first seizure (age, type, duration,
fever), seizures during the course (type, fever sensitivity),
SE (age of onset, number, fever), photosensitivity, and
treatment (age at stiripentol introduction, administration
of an inappropriate medication for less than three
months).
However, for patients over the age of three years (i.e.
when the cognitive delay is almost constant), IQ/DQ
was significantly lower for patients exhibiting myoclonic
(p = .03) or focal seizures (p = .03). This remained signifi-
cant when only the mutated children were considered
(notice that none of the nine non-mutated patients were
evaluated before three years of age in the present series).
Cognitive development and epilepsy according to genetics
There was no difference for demographic data, the age
at first and last observation and for the duration of
follow-up between patients with and without SCN1A
mutation. However, the occurrence of another DS case
in the family was only reported in the SCN1A-mutated
group and the patients with intrauterine growth retard-
ation were all three mutated.
Although there was no significant difference for last
DQ/IQ according to whether there was or not SCN1A
mutation, the mutated and non-mutated groups exhibited
different psychomotor outcome according to their
pediatric neurologist (Table 1). The semi-quantitative
evaluation (SQPS) showed that no patient had severe delay
in the non-mutated group whereas all patients labeled
severe delay (26%) were in the mutated group. All the
patients classified with severe delay using this scale had
DQ/IQ < 50.
Similarly, gait and language skills tended to be more fa-
vorable in the non-mutated group. Gait was considered
normal by the clinician in 44% of the non-mutated patients
but abnormal in 77.5% of SCN1A + group (p = 0.017).
Language was normally structured in all SCN1A- patients
but only in 47% (27/58) of SCN1A + patients. However,
given the small size of the non-mutated group, these differ-
ences did not reach statistical significance.
Regarding epilepsy, there was no difference between
both groups for first seizure (age, type, fever), photosensi-
tivity and treatment, but tonic seizures were more
frequent in the non-mutated than in the mutated patients(Fisher exact: p = .04). In addition, age at first SE tended to
be lower in the non mutated group: SE occurred before
6 months in 67% of the non mutated patients vs 26% of
the mutated ones (Fisher exact: p = .02). SE also tended to
be more frequent in the none mutated than the mutated
group (mean number 4.4 vs 2.5, p = .09).
Discussion
Based on a large and homogeneous population of children
with typical DS mostly prospectively and partly longitu-
dinally assessed for cognitive development, this study
shows that although retardation worsens with age, there is
no loss of abilities and patients make slow but regular pro-
gress along the first decade. As suspected, cognitive
outcome is related to epilepsy course and seizure charac-
teristics since myoclonia and focal seizures are associated
with a lower QD/IQ level after 3 years of age. However,
epilepsy does not account for the whole cognitive picture
since mutated patients tend to exhibit worse psychomotor
course than non-mutated ones although epilepsy tends to
be less severe. SCN1A mutation is therefore a key factor of
cognitive delay, in addition to epilepsy. We also observe a
dissociated cognitive profile, particularly for patients with
SCN1A mutation: speech develops better than visuo-
motor function, from the first years of life and before
cognitive slowing that occurs mainly after age three.
Methodological issues
Although many scales have been developed and validated
to investigate cognitive functions, none is appropriate for
patients who cannot follow regular schooling. Scales for
psychomotor development (Brunet-Lezine and Denver)
are most sensitive to age and lack sensitivity in the context
of slow but protracted acquisitions [19]. Scales for
intelligence (WISC and WPPSI) lose sensitivity under IQ
values of 50, and subtests for DQ/IQ require minimal
scores of 60 to be performed [17,18]. Other scales devel-
oped for severely delayed children do not address cogni-
tion. The Vineland scale evaluates adaptation to the
surrounding and is very sensitive to parents’ level of
education, which precludes reliable comparison between
patients [22]. The same holds for quality of life scales [21].
In order to overcome this challenge, we applied several
scales to each child and focused on the youngest children
since they had made enough acquisitions to be compar-
able to their age mates.
The lack of psychomotor deterioration
DS patients usually experience a slowing of cognitive
achievements that becomes evident after the first year of
life, and they reach the low DQ/IQ level by five years of
age [7,8,10]. Whether the patients then continue deteri-
orating or stabilize at this low level has been debated.
Data drawn from a first prospective study in 12 subjects
Nabbout et al. Orphanet Journal of Rare Diseases 2013, 8:176 Page 7 of 8
http://www.ojrd.com/content/8/1/176indicated stabilization in all of them, including the six
with typical DS [14]. Our findings show that although
the condition worsens progressively compared to healthy
children there is no loss of abilities since all patients
acquired new skills during follow-up. Obviously, this
does not apply to the rare patients who had developed
major anoxic-ischemic sequelae after severe and compli-
cated status epilepticus with atrophy of supratentorial
structures [23] or lesions in the subcortical structures
[24] and who were therefore not included in the present
study.
Epilepsy cannot completely explain the cognitive course
DS is often referred to as an epileptic encephalopathy
[5-8]. Indeed, there is progressive worsening of the cogni-
tive defect along the occurrence of pharmacoresistant epi-
leptic seizures and in two series cognitive impairment was
linked to the frequency of convulsive seizures [7] and the
presence of SE or EEG spikes [8]. However, discordant
results have emerged from one case report and a retro-
spective series [9,10]. Our series also found no correlation
between the severity of cognitive delay and that of seizure
activity. As in Ragona’s study [10], cognitive scores were
only related to non-convulsive seizures for the sub-
population of patients over three years of age, thus when
patients were the most delayed. Minor seizures consisted
of myoclonus and “absences” in Ragona’s series [11], but
of myoclonus and complex partial seizures in ours. How-
ever, the distinction between “absences” and “complex
partial seizures” may be debatable, given the difficulty per-
forming ictal EEG records in such poorly cooperating chil-
dren and adolescents. Moreover, in our series, patients
without SCN1A mutation tended to be more preserved
than the mutated ones for both motor and speech skills,
although their epilepsy characteristics were those that are
usually associated with poor cognitive outcome: tonic
seizures, earlier onset of SE and higher number of SE, thus
hallmarks of severe epileptic encephalopathy [25].
DS does therefore not correspond to the usual defin-
ition of epileptic encephalopathy, i.e. worsening of
function as a consequence of epileptic activity itself. It is
possible that SCN1A alteration per se plays a role in
psychomotor delay, affecting structures/pathways not
involved in epilepsy. Although we cannot exclude other
genetic factors, this finding should encourage the search
of alternative explanations for the motor and cognitive
delay, the identification of which could offer more
appropriate targets for future treatment.
SCN1A mutation likely plays a central role on other
pathways than those devoted to epilepsy
The dissociated cognitive profile is a major characteristic
of DS patients, consisting in a worse impact on visuo-
spatial than speech abilities, found in our series as intwo previous reports [7,10]. Main troubles include visual
motor integration and visual perception, and are associ-
ated with impairment of attention. Furthermore, in our
series as in Chieffo et al’s patients, visuomotor disorders
were detected from the first year of life, several months
before the cognitive decline could be identified [26].
Since this trouble was not related to age, the hypothesis
of a maturational delay - maturation of the right hemi-
sphere is known to precede that of the left hemisphere
in right-handed healthy infants [27] – is excluded.
Hypothesis of cerebellar dysfunction has been proposed
[26].
Another marker of possible cerebellar dysfunction is
ataxia, a component of the clinical pattern from the first
steps of patients with DS [1,2], even before any episode
of SE has occurred, and before the administration of any
medication that could account for ataxia as a side effect,
such as benzodiazepines. Myoclonus also is often associ-
ated with cerebellar dysfunction, in animal models as in
human disease, in progressive and non-progressive con-
ditions [28-31].
Considering that Nav 1.1, the protein determined by
the SCN1A gene, is expressed in the initial segment of
inhibitory neurons of the cerebellum in addition to the
cerebral cortex, in transgenic mice [32], cerebellar dys-
function is likely a constitutive component of DS and
could contribute to the occurrence of altogether the
myoclonus, the gait disorders and the cognitive delay.
This study shows that although the psychomotor/cog-
nitive delay worsens with age, there is no regression in
DS patients. Their encephalopathy is not a pure conse-
quence of epilepsy, but SCN1A mutation seems to play
an additional direct role. Altogether, these results plead
for DS encephalopathy being genetic as well as epileptic
in origin.
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